Oncology Medical News about soft-tissue sarcoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Trabectedin for the management of soft-tissue sarcoma
Expert Review of Anticancer Therapy, 06/08/09

Boudou L et al. – Article outlines the therapeutic effects of Trabectedin (a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA-repair machinery) in the treatment of soft-tissue sarcoma and other cancers:

Trabectedin shows promising single-agent activity in pretreated pts with soft-tissue sarcoma (STS) and ovarian and breast cancer
Combination with various other chemotherapeutic drugs is also feasible
Toxicities observed:
- Mainly hematological and hepatic; grade 3-4 neutropenia and thrombocytopenia observed in 50 and 20% of pts, respectively, and
- Grade 3-4 elevation of liver transaminases observed in 35-50% of pts treated with trabectedin
Trabectedin obtained regulatory approval by the EMEA and in other countries for the treatment of STS pts after failure of all available standard-of-care chemotherapy
Current research focuses on the identification of predictive factors for pts treated with trabectedin and development of other combination

<< Previous
Positive expression of ERCC1 predicts a poorer platinum-based...

Next >>
The Influence of Tumor-Host Interactions in the Stromal...